Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences-Reference-Cited by-同舟云学术

Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences

Published:2023-09 Issue:5 Volume:18 Page:727-734
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Barrientos Jacqueline C.,Ayed Ayed O.,Cha Agnes,Du Senxi,Fang Bruno,Hall Ryan,Marks Stanley M.,Peng Eileen,Rhodes Joanna M.,Ryan Kellie,Winters Sharon B.,Yeung Percy L.,Hou Jing-Zhou^ORCID

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-023-00988-0.pdf

Reference31 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.

2. Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, et al. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk. 2011;11(6):498–506. https://doi.org/10.1016/j.clml.2011.07.002.

3. Kittai AS, Huang Y, Bhat SA, Paskett ED, Rogers KA, Barrientos J, et al. Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006–2019. Blood Adv. 2023;7(11):2575–9. https://doi.org/10.1182/bloodadvances.2022008643.

4. Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849–61. https://doi.org/10.1200/JCO.19.03355.

5. Vardell V, Ermann DA, Shah H, Fitzgerald L, Hu B, Stephens DM. Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic lymphoma [abstract 7508]. J Clin Oncol. 2022;40(16):7508. https://doi.org/10.1200/JCO.2022.40.16_suppl.7508.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ibrutinib;Reactions Weekly;2024-05-18